Evommune, Inc. (EVMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evommune, Inc. (EVMN) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.70 Million) by net assets ($205.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EVMN market cap overview for the company's overall valuation and market capitalisation.
Evommune, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evommune, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evommune, Inc. ranked by their cash flow conversion efficiency. See Evommune, Inc. cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mangalam Cement Limited
NSE:MANGLMCEM
|
0.019x |
|
Joyvio Agriculture Development Co Ltd
SHE:300268
|
-0.016x |
|
AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust
BK:AIMIRT
|
0.013x |
|
Rana Gruber AS
OL:RANA
|
0.544x |
|
GENERALFINANCE SPA
F:VG30
|
-0.212x |
|
Selvaag Bolig ASA
OL:SBO
|
0.106x |
|
Inmobiliaria del Sur SA
MC:ISUR
|
-0.025x |
|
Semperit Aktiengesellschaft Holding
VI:SEM
|
0.050x |
Annual Cash Flow Conversion Efficiency for Evommune, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of Evommune, Inc. from 2023 to 2025. View EVMN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $205.57 Million | $-76.44 Million | -0.372x | -192.17% |
| 2024-12-31 | $-144.24 Million | $-58.20 Million | 0.403x | +4.62% |
| 2023-12-31 | $-77.71 Million | $-29.97 Million | 0.386x | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more